Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Journal Article

Local Library Link: Find It @ Loyola

Authors: Gopal, A. K.; Ramchandren, R.; O'Connor, O. A.; Berryman, R. B.; Advani, R. H.; Chen, R; Smith, S. E.; Cooper, M.; Rothe, A.; Matous, J. V.; Grove, L. E.; Zain, J.
Article Title: Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
Abstract: Hodgkin lymphoma (HL) relapsing after allogeneic stem cell transplantation (alloSCT) presents a major clinical challenge. In the present investigation, we evaluated brentuximab vedotin, a CD30-directed Ab-drug conjugate, in 25 HL patients (median age, 32 years; range, 20-56) with recurrent disease after alloSCT (11 unrelated donors). Patients were > 100 days after alloSCT, had no active GVHD, and received a median of 9 (range, 5-19) prior regimens. Nineteen (76%) had refractory disease immediately before enrollment. Patients received 1.2 or 1.8 mg/kg of brentuximab vedotin IV every 3 weeks (median, 8 cycles; range, 1-16). Overall and complete response rates were 50% and 38%, respectively, among 24 evaluable patients. Median time to response was 8.1 weeks, median progression-free survival was 7.8 months, and the median overall survival was not reached. Cough, fatigue, and pyrexia (52% each), nausea and peripheral sensory neuropathy (48% each), and dyspnea (40%) were the most frequent adverse events. The most common adverse events >/= grade 3 were neutropenia (24%), anemia (20%), thrombocytopenia (16%), and hyperglycemia (12%). Cytomegalovirus was detected in 5 patients (potentially clinically significant in 1). These results support the potential utility of brentuximab vedotin for selected patients with HL relapsing after alloSCT.
Journal Title: Blood
Volume: 120
Issue: 3
ISSN: 1528-0020; 0006-4971
Publisher: American Society of Hematology  
Journal Place: United States
Date Published: 2012
Start Page: 560
End Page: 568
Language: eng
DOI/URL:

10.1182/blood-2011-12-397893
Notes: LR: 20131107; ClinicalTrials.gov/NCT00947856; ClinicalTrials.gov/NCT01026233; ClinicalTrials.gov/NCT01026415; GR: K12 CA001727/CA/NCI NIH HHS/United States; JID: 7603509; 0 (Antineoplastic Agents); 0 (Immunoconjugates); 0 (cAC10-vcMMAE); OID: NLM: PMC3731651; 2012/04/17 [aheadofprint]; ppublish